(Q46484275)

22 December 2017

title

PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose (English)

1 reference

22 December 2017

author name string

Panchapakesan U

1

1 reference

22 December 2017

Sumual S

2

1 reference

22 December 2017

Pollock CA

3

1 reference

22 December 2017

Chen X

4

1 reference

22 December 2017

publication date

10 May 2005

1 reference

22 December 2017

American Journal of Physiology - Renal Physiology

published in

1 reference

22 December 2017

volume

289

1 reference

22 December 2017

issue

5

1 reference

22 December 2017

page(s)

F1153-8

1 reference

22 December 2017

ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1.

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Rosiglitazone reduces urinary albumin excretion in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Physiological and therapeutic roles of peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Dimethylsulfoxide induces upregulation of tumor suppressor protein PTEN through nuclear factor-kappaB activation in HL-60 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Preventing microalbuminuria in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

c-Fos-driven transcriptional activation of transforming growth factor β-1: inhibition of high glucose-induced promoter activity by thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Coactivator and corepressor complexes in nuclear receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00097.2005

10.1152/AJPRENAL.00097.2005

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017